ArriVent BioPharma, Inc. (NASDAQ:AVBP – Get Free Report) was the recipient of a significant decrease in short interest during the month of November. As of November 15th, there was short interest totalling 3,120,000 shares, a decrease of 11.9% from the October 31st total of 3,540,000 shares. Based on an average daily volume of 275,700 shares, the short-interest ratio is currently 11.3 days. Approximately 16.1% of the company’s stock are short sold.
Analyst Upgrades and Downgrades
AVBP has been the topic of several analyst reports. HC Wainwright restated a “buy” rating and set a $36.00 price objective on shares of ArriVent BioPharma in a report on Friday, November 15th. The Goldman Sachs Group upped their price target on shares of ArriVent BioPharma from $28.00 to $38.00 and gave the company a “buy” rating in a report on Tuesday, September 10th. Citigroup boosted their target price on shares of ArriVent BioPharma from $30.00 to $36.00 and gave the stock a “buy” rating in a research report on Wednesday, September 11th. Finally, Oppenheimer reaffirmed an “outperform” rating and set a $39.00 price target (up previously from $35.00) on shares of ArriVent BioPharma in a research report on Tuesday, September 10th. Five analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average price target of $36.80.
Check Out Our Latest Stock Analysis on ArriVent BioPharma
Institutional Inflows and Outflows
ArriVent BioPharma Stock Up 2.9 %
ArriVent BioPharma stock opened at $29.96 on Friday. ArriVent BioPharma has a 12 month low of $14.35 and a 12 month high of $36.37. The company has a fifty day moving average price of $28.63 and a two-hundred day moving average price of $23.78.
ArriVent BioPharma Company Profile
ArriVent BioPharma, Inc operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers in the United States. It also engages in the development and commercialization of targeted cancer therapies for non-small cell lung cancer (NSCLC) and other solid tumors.
Read More
- Five stocks we like better than ArriVent BioPharma
- How to Choose Top Rated Stocks
- Analog Devices: Why the Uptrend Could Accelerate in 2025
- How to Invest in Small Cap StocksĀ
- Texas Pacific Land: Permian Basin Powerhouse With an AI Edge
- Why Invest in High-Yield Dividend Stocks?
- ServiceNow: Will the High-Flyer Finally Split in 2024?
Receive News & Ratings for ArriVent BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ArriVent BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.